PharmaCielo (PCLOF)
OTHER OTC:PCLOF
Want to see PCLOF full AI Analyst Report?
PCLOF Stock Chart & Stats
$0.01
<$0.01(6.14%)
At close: 4:00 PM EST
$0.01
<$0.01(6.14%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.12
Previous CloseN/A
Volume1.75K
Average Volume (3M)9.90K
Market Cap
$8.35M
Enterprise Value$32.46M
Total Cash (Recent Filing)$289.24K
Total Debt (Recent Filing)$18.65M
Price to Earnings (P/E)5.2
Beta-1.89
Next Earnings
Jun 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding187,983,690
10 Day Avg. Volume17,743
30 Day Avg. Volume9,897
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market Cap3.89
Enterprise Value/Revenue12.43
Enterprise Value/Gross Profit42.91
Enterprise Value/Ebitda-32.37
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B Cannabinoid Ingredient ModelA B2B focus on standardized cannabinoid inputs targets institutional customers with repeatable demand and higher quality requirements. This business model can generate steadier order streams and contract relationships versus consumer retail, supporting more durable revenue if regulatory access and customer approvals are secured.
Positive Gross Margin (~29%)A positive gross margin indicates the core extraction and processing economics can be viable at product level. If management sustains or expands volumes, operating leverage could convert product-level profitability into improved operating results over months, supporting a path toward breakeven when fixed costs are absorbed.
Vertical Cultivation & Processing CapabilitiesOwning cultivation and extraction capability offers control of input quality, traceability and potential cost advantages versus pure-play buyers. Vertical integration supports consistency required by medical/wellness customers and can be a durable competitive advantage for scaling standardized ingredient production if capacity utilization improves.
Bears Say
Declining RevenueFalling revenue erodes the base needed to cover fixed costs and realize operating leverage. Continued top-line contraction over trailing periods raises structural concerns about demand, customer retention or commercial execution, making consistent margin improvement and cash generation harder to sustain without new sales traction.
Negative Equity & High LeverageSignificant negative equity and debt materially constrain financial flexibility. High leverage relative to a small asset base elevates refinancing and solvency risk, limits access to traditional capital, and increases the chance that future raises dilute stakeholders or that debt terms constrain strategic decisions over the medium term.
Persistent Negative Cash GenerationOngoing negative operating and free cash flow means the company needs external funding to sustain operations and service debt. Even with improvement versus prior years, continued cash burn restricts reinvestment in growth or margin expansion and raises structural dilution and refinancing risks over the coming months.
PharmaCielo News
PCLOF FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was <$0.01 and its highest was $0.12 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is $8.35M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is Jun 01, 2026 which is in 7 days.
How were PharmaCielo’s earnings last quarter?
Currently, no data Available
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 187,983,690 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in PCLOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., together with its subsidiary, cultivates, processes, produces, and supplies medicinal-grade cannabis extracts, tetrahydrocannabinol, and related products. The company also offers telemedicine software. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies in Canada and Colombia. The company has a strategic alliance with AssuredTrans Inc. PharmaCielo Ltd. is headquartered in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―
Ownership Overview
16.47% Insiders
0.16% Other Institutional Investors
83.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---